The Effects on Visceral Fat and Cardiovascular Risk Factors of Testosterone Replacement in Secondary Hypogonadal Men.
10.3803/jkes.2005.20.3.252
- Author:
Eui Sil HONG
1
;
Sung Yeon KIM
;
Young Ju CHOI
;
Sang Wan KIM
;
Chan Soo SHIN
;
Kyong Soo PARK
;
Hak Chul JANG
;
Seong Yeon KIM
;
Bo Youn CHO
;
Hong Kyu LEE
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Hypogonadal men;
Testosterone replacement;
Visceral fat;
Cardiovascular risk factors
- MeSH:
Adipose Tissue;
Body Composition;
Cardiovascular Diseases;
Cholesterol;
Cholesterol, HDL;
Coronary Disease;
Fasting;
Homocysteine;
Humans;
Hypogonadism;
Incidence;
Insulin;
Insulin Resistance;
Interleukin-6;
Intra-Abdominal Fat*;
Male;
Multiple Endocrine Neoplasia Type 1;
Obesity, Abdominal;
Plasma;
Risk Factors*;
Testosterone*;
Tomography, X-Ray Computed
- From:Journal of Korean Society of Endocrinology
2005;20(3):252-260
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Increased body fat, abdominal obesity and insulin resistance are important clinical features in hypogonadal men. Several studies have demonstrated that a low testosterone concentration in men is associated with coronary heart disease, visceral obesity and insulin resistance. In this study, the effects of testosterone replacement therapy on the abdominal visceral fat and cardiovascular risk factors in hypogonadal men were investigated. METHODS: We selected 26 men with secondary hypogonadism (mean serum testosterone+/-SD 0.39+/- 0.57ng/mL), who were then treated with testosterone for 12 months. We measured the body composition, including the abdominal visceral fat area by abdominal CT at the L4 level, both before and 12 months after treatment, and the lipid profile, fasting plasma insulin, HOMA-IR and the serum homocysteine, CRP and IL-6 before and 6, 12 months after treatment. RESULTS: With respect to the body composition, the lean body mass had significantly increased 12 months after treatment(P= 0.002), but there were no significant changes in the body fat mass and abdominal visceral fat area. There was a trend toward a decreased fasting plasma insulin and HOMA-IR, but this did not reach statistical significance. The total cholesterol had decreased significantly at 12 months(P=0.04) and the HDL cholesterol decreased significantly over the course of study(P=0.02). There were no significant changes in the serum homocysteine, CRP and IL-6 after treatment. CONCLUSIONS: After 12 months testosterone replacement therapy in the 26 men with hypogonadism, the lean body mass had increased significantly, but there was no significant change on the abdominal visceral fat during the treatment period. Testosterone replacement had deleterious effect on HDL cholesterol, but not significant effects on insulin resistance and the serum homocysteine, CRP and IL-6. These results suggest that testosterone replacement therapy may have a few adverse effects on cardiovascular diseases in hypogonadal men. However, it will be necessary to examine the long-term effects of testosterone replacement on the incidence of cardiovascular events as well as the cardiovascular risk factors in men with hypogonadism
